Showing 5001-5010 of 6934 results for "".
- Study: Dual-Action Topical Treatment Reduces Lesion Counts in Adult Acne Patientshttps://practicaldermatology.com/news/study-dual-action-topical-treatment-reduces-lesion-counts-adult-acne-patients/2470855/Results from a recent pilot study suggested that a combination therapy of clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel with clascoterone 1% cream was effective in reducing lesions in adult acne patients. Researchers for the study enrolled 20 adult participants with
- Skin Cancer Foundation Names New Executive Directorhttps://practicaldermatology.com/news/skin-cancer-foundation-names-new-executive-director/2470856/The Skin Cancer Foundation (SCF), a national nonprofit organization that is committed to decreasing the incidence and mortality of the world’s most common cancer through public education, announced that it has appointed Becky Kamowitz to the role of executive director. Kamowitz has worked
- Genetic Study Reveals Psoriasis-Sudden Hearing Loss Connectionhttps://practicaldermatology.com/news/genetic-study-reveals-psoriasis-hearing-loss-connection/2470853/A recent genetic study has established a causal relationship between psoriasis and an elevated risk of sudden sensorineural hearing loss (SSNHL). Researchers derived the findings using Mendelian randomization (MR) analysis to identify potential connections between inflammatory skin disease
- Hair Care Market to Reach $20B by 2029: Reporthttps://practicaldermatology.com/news/hair-care-market-reach-20b-2029-report/2470831/The U.S. hair care market is projected to reach $20 billion by 2029, according to a report released by ResearchAndMarkets.com. The report noted that hair care remains resilient despite economic fluctuations due to consumer demand for premium and sustainable products and cited the rising p
- Knight Dermatology Institute Partners With Forefront Dermatologyhttps://practicaldermatology.com/news/knight-dermatology-institute-partners-forefront-dermatology/2470808/Knight Dermatology Institute (KDI) and Forefront Dermatology have formed a partnership, Physician Growth Partners (PGP) announced in a press release. Based in Orlando, Florida, KDI is a medically and surgically driven practice with a core focus on skin cancer detection, prevention, and tre
- Report: Regenerative Aesthetics Exosome Market Poised for Growth Through 2031https://practicaldermatology.com/news/report-regenerative-aesthetics-exosome-market-poised-355-cagr-through-2031/2470805/The global regenerative aesthetics exosome products market is projected to experience a compound annual growth rate (CAGR) of 35.5% from 2024 to 2031, according to a report from InsightAce Analytic. Exosome-based therapies with applications in skin rejuvenation, hair restoration, scar redu
- Study: Ongoing Inequities in Dermatology Productivity Metricshttps://practicaldermatology.com/news/study-ongoing-inequities-dermatology-productivity-metrics/2470777/A new study in JAMA Dermatology revealed that while the 2021 Medicare physician fee schedule updates reduced inequities in work relative value units (wRVUs) for outpatient dermatology visits, significant disparities based on patient demographics persist. Analyzing data from 89,656
- Review: Potential and Challenges for Exosomes in Cosmetic Dermatologyhttps://practicaldermatology.com/news/review-potential-and-challenges-exosomes-cosmetic-dermatology/2470764/Exosomes show promise for enhancing skin and hair health, but key challenges must be addressed before they can be widely adopted in cosmetic dermatology, according to a new literature review in the Journal of Drugs in Dermatology. Exosomes, extracellular vesicles responsible for cellular c
- Arcutis Submits sNDA for Roflumilast for Children 2 to 5 With ADhttps://practicaldermatology.com/news/arcutis-submits-snda-roflumilast-children-2-5-ad/2470667/Arcutis Biotherapeutics, Inc. announced the submission of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) for roflumilast (ZORYVE) cream 0.05%, a once-daily, next-generation phosphodiesterase 4 (PDE4) inhibitor, for the topical treatment of mild-to-moderate
- AARS Scholar Grant to Be Used for Antibiotics Researchhttps://practicaldermatology.com/news/aars-scholar-grant-be-used-antibiotics-research/2470665/The American Acne and Rosacea Society (AARS) announced that the 2024 AARS Clinical Research Scholar Grant has been provided to Jean McGee, MD, PhD, of the Department of Dermatology at Brigham and Women’s Hospital in Boston. Additionally, AARS Clinical Research Grants are being provided to